MAZE — Maze Therapeutics, Inc.
MAZE dilution and offerings
- Dilution risk: Low
- Active shelf: S-3ASR (Feb 2026)
- Float: 40.0M shares
🔔 Alert me if MAZE files an offering or S-3
$30.37-3.53%
Last close: · regular session
Last 60 sessions
Dilution risk: low; active automatic shelf (S-3ASR, Feb 2026). Float: 40.0M shares. Latest SEC filing: 144 on Nov 2, 2026. MAZE closed at $30.37 (-3.53%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for MAZE in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 125
- Website: https://www.mazetx.com
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Latest SEC filings for MAZE
Latest MAZE news
- Maze Therapeutics to Participate in Upcoming Investor Conferences Read article
- What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock Read article
- How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39% Read article
- Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026 Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.